A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/04 (2006.01) A61K 38/12 (2006.01) C07K 7/04 (2006.01) C07K 7/64 (2006.01) C07K 14/705 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2293666
The present invention relates to peptidomimetics capable of inhibiting CD28 and/or CTLA-4 interaction with CD80 (B7-1) and CD86 (B7-2) and having a core amino acid sequence, LeuMetTyrProProProTyrTyr, corresponding to residues 2 to 9 of SEQ ID NO:1. The present invention also relates to pharmaceutical compositions and a method of treating pathologies and disorders which are improved by inhibition of CD28 and/or CTLA-4 interaction with CD80 and CD86.
La présente invention a trait à des peptidomimétiques capables d'inhiber l'interaction de CD28 et/ou CTLA-4 avec CD80 (B7-1) et CD86 (B7-2), et présentant une séquence d'acides aminés centrale, LeuMetTyrProProProTyrTyr, qui correspond aux résidus 2 à 9 de SEQ ID NO:1. La présente invention a également trait à des compositions pharmaceutiques et à une méthode de traitement de pathologies et de troubles auxquels il est possible de remédier par l'inhibition de l'interaction de CD28 et/ou CTLA-4 avec CD80 et CD86.
Blechner Steven
El Tayar Nabil
Jameson Brad
Tepper Mark
Applied Research Systems Ars Holding N.v.
Kirby Eades Gale Baker
Laboratoires Serono S.a.
LandOfFree
Cd28/ctla-4 inhibiting peptidomimetics, pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cd28/ctla-4 inhibiting peptidomimetics, pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cd28/ctla-4 inhibiting peptidomimetics, pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1547431